Brain protection by transamniotic stem cell therapy (TRASCET) in a model of intrauterine growth restriction (IUGR)

Topic overview

Experimental study demonstrates that transamniotic stem cell therapy (TRASCET) using mesenchymal stem cells reduces neuroinflammation and improves brain growth in a rat model of intrauterine growth restriction. Primed MSCs showed superior anti-inflammatory effects, significantly reducing TNF-α and IL-1β levels in fetal brains compared to untreated controls.

Key takeaways

TRASCET with primed MSCs significantly reduced brain inflammation markers (TNF-α, IL-1β) in IUGR rat fetuses compared to untreated controls
Priming MSCs with IFN-γ and IL-1β before transamniotic injection enhanced anti-inflammatory effects versus non-primed cells
Both primed and non-primed TRASCET significantly increased fetal brain weights in IUGR model compared to untreated/sham groups
Transamniotic delivery of MSCs may protect fetal brain development by attenuating neuroinflammation in growth-restricted pregnancies

Keywords

Intrauterine Growth Restriction Mesenchymal Stem Cells Fetal Therapy Neuroprotection Neuroinflammation Transamniotic Injection

Hashtags

#FetalTherapy #StemCellTherapy #IUGR #Neuroprotection

Comments

Loading comments...